Aug. 17 at 4:51 PM
$RVMD $SLS My Longs Brothers and Sisters just Imagine for a second when GPS Regal Pivotal Registrational Phase 3 study shows triple the OS compared to
$RVMD Phase 3 RASolute 302 trial showing a median overall survival of 13.2 months versus 6.7 months for chemotherapy.
$SLS Breakthrough results will shake the foundation of entire Oncology/Hematology sector not seen in a Millennia. ✌️🙏❤️🩹